Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model

Acta Neuropathologica Communications

Volumn 4, Issue 1, 2016, Pages

  Scheffold, Annika ^a   Holtman, Inge R ^b   Dieni, Sandra ^c   Brouwer, Nieske ^b   Katz, Sarah Fee ^d   Jebaraj, Billy Michael Chelliah ^a   Kahle, Philipp J ^e   Hengerer, Bastian ^f   Lechel, André ^d   Stilgenbauer, Stephan ^a   Boddeke, Erik W G M ^b   Eggen, Bart J L ^b   Rudolph, Karl Lenhard ^g   Biber, Knut ^b,c  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^g FRITZ LIPMANN INSTITUTE   (Germany)

Author keywords

Microglia; Parkinson's disease; Telomeres; synuclein

Indexed keywords

ALPHA SYNUCLEIN; MESSENGER RNA; SNCA PROTEIN, HUMAN;

ANIMAL; BODY EQUILIBRIUM; BRAIN STEM; C57BL MOUSE; DISEASE COURSE; HUMAN; METABOLISM; MICROGLIA; MOTOR ACTIVITY; PARKINSONISM; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; PROTEINOSIS; TELOMERE SHORTENING; TIME FACTOR; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN STEM; DISEASE PROGRESSION; HUMANS; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PHENOTYPE; POSTURAL BALANCE; PROTEIN AGGREGATION, PATHOLOGICAL; RNA, MESSENGER; TELOMERE SHORTENING; TIME FACTORS;

EID: 85014509915     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/s40478-016-0364-x     Document Type: Article

References (89)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5:525-35.
2. Xu W, Tan L, Yu JT. Link between the SNCA gene and parkinsonism. Neurobiol Aging. 2015;36:1505-18.
3. Goedert M, Spillantini MG, Serpell LC, Berriman J, Smith MJ, Jakes R, et al. From genetics to pathology: tau and alphα-synuclein assemblies in neurodegenerative diseases. Philos Trans R Soc Lond B Biol Sci. 2001;356:213-27.
4. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, et al. Aggregation of alphα-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol. 1998;152:879-84.
5. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that alphα-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011;108:4194-9.
6. Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in alphα-synuclein fibril formation. J Biol Chem. 2001;276:10737-44.
7. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, et al. Detection of oligomeric forms of alphα-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006;20:419-25.
8. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, et al. Different species of alphα-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007;27:9220-32.
9. Biber K, Moller T, Boddeke E, Prinz M. Central nervous system myeloid cells as drug targets: current status and translational challenges. Nat Rev Drug Discov. 2016;15:110-24.
10. Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Perdiguero EG, et al. Microglia emerge from erythromyeloid precursors via Pu.1-and Irf8-dependent pathways. Nat Neurosci. 2013;16:273-80.
11. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841-5.
12. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336:86-90.
13. Tremblay ME, Lowery RL, Majewska AK. Microglial interactions with synapses are modulated by visual experience. PLoS Biol. 2010;8:e1000527.
14. Sierra A, Navascues J, Cuadros MA, Calvente R, Martin-Oliva D, Ferrer-Martin RM, et al. Expression of inducible nitric oxide synthase (iNOS) in microglia of the developing quail retina. PLoS One. 2014;9:e106048.
15. Tremblay ME, Lowery RL, Majewska AK. Microglial interactions with synapses are modulated by visual experience. PLoS Biol. 2011;8:e1000527.
16. Biber K, Owens T, Boddeke E. What is microglia neurotoxicity (Not)? Glia. 2014;62:841-54.
17. Butovsky O, Jedrychowski MP, Cialic R, Krasemann S, Murugaiyan G, Fanek Z, et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol. 2015;77:75-99.
18. Hanisch UK. Functional diversity of microglia-how heterogeneous are they to begin with? Front Cell Neurosci. 2013;7:65.
19. Hellwig S, Heinrich A, Biber K. The brain's best friend: microglial neurotoxicity revisited. Front Cell Neurosci. 2013;7:71.
20. Kettenmann H, KirchhoffF, Verkhratsky A. Microglia: new roles for the synaptic stripper. Neuron. 2013;77:10-8.
21. London A, Cohen M, Schwartz M. Microglia and monocyte-derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair. Front Cell Neurosci. 2013;7:34.
22. Sierra A, Beccari S, Diaz-Aparicio I, Encinas JM, Comeau S, Tremblay ME. Surveillance, phagocytosis, and inflammation: how never-resting microglia influence adult hippocampal neurogenesis. Neural Plast. 2013;2014:610343.
23. Vinet J, Weering HR, Heinrich A, Kalin RE, Wegner A, Brouwer N, et al. Neuroprotective function for ramified microglia in hippocampal excitotoxicity. J Neuroinflammation. 2012;9:27.
24. Brück DW, GK. Stefanova, N. Fellner, L. Glia and alphα-synuclein in neurodegeneration: A complex interaction. Neurobiol Dis. 2016;85: 262-74.
25. Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? Int Rev Neurobiol. 2007;82:235-46.
26. Power JH, Blumbergs PC. Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol. 2009;117:63-73.
27. Calne DB, Eisen A, McGeer E, Spencer P. Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotrophic interaction between ageing and environment? Lancet. 1986;2:1067-70.
28. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283-301.
29. Hornykiewicz O. Ageing and neurotoxins as causative factors in idiopathic Parkinson's disease-a critical analysis of the neurochemical evidence. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13:319-28.
30. Perry VH. Stress primes microglia to the presence of systemic inflammation: implications for environmental influences on the brain. Brain Behav Immun. 2007;21:45-6.
31. Blackburn EH. Telomere states and cell fates. Nature. 2000;408:53-6.
32. Damjanovic AK, Yang Y, Glaser R, Kiecolt-Glaser JK, Nguyen H, Laskowski B, et al. Accelerated telomere erosion is associated with a declining immune function of caregivers of Alzheimer's disease patients. J Immunol. 2007;179:4249-54.
33. Lechel A, Holstege H, Begus Y, Schienke A, Kamino K, Lehmann U, et al. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology. 2007;132:1465-75.
34. Flanary BE, Streit WJ. Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes. Glia. 2004;45:75-88.
35. Flanary BE, Streit WJ. Telomeres shorten with age in rat cerebellum and cortex in vivo. J Anti Aging Med. 2003;6:299-308.
36. Flanary BE, Sammons NW, Nguyen C, Walker D, Streit WJ. Evidence that aging and amyloid promote microglial cell senescence. Rejuvenation Res. 2007;10:61-74.
37. Guan JZ, Maeda T, Sugano M, Oyama J, Higuchi Y, Suzuki T, et al. A percentage analysis of the telomere length in Parkinson's disease patients. J Gerontol A Biol Sci Med Sci. 2008;63:467-73.
38. Watfa G, Dragonas C, Brosche T, Dittrich R, Sieber CC, Alecu C, et al. Study of telomere length and different markers of oxidative stress in patients with Parkinson's disease. J Nutr Health Aging. 2009;15:277-81.
39. Wang H, Chen H, Gao X, McGrath M, Deer D, De Vivo I, et al. Telomere length and risk of Parkinson's disease. Mov Disord. 2008;23:302-5.
40. Maeda T, Guan JZ, Koyanagi M, Higuchi Y, Makino N. Aging-associated alteration of telomere length and subtelomeric status in female patients with Parkinson's disease. J Neurogenet. 2012;26:245-51.
41. Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, et al. Selective insolubility of alphα-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol. 2001;159: 2215-25.
42. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci. 2000;20:6365-73.
43. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, et al. Misfolded proteinase K-resistant hyperphosphorylated alphα-synuclein in aged transgenic mice with locomotor deterioration and in human alphα-synucleinopathies. J Clin Invest. 2002;110:1429-39.
44. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 1997;91:25-34.
45. Carter RJ, Morton J, Dunnett SB. Motor coordination and balance in rodents. Curr Protoc Neurosci. 2001;Chapter 8:Unit 8 12.
46. Bevins RA, Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'. Nat Protoc. 2006;1:1306-11.
47. Freichel C, Neumann M, Ballard T, Muller V, Woolley M, Ozmen L, et al. Age-dependent cognitive decline and amygdala pathology in alphasynuclein transgenic mice. Neurobiol Aging. 2007;28:1421-35.
48. Satyanarayana A, Wiemann SU, Buer J, Lauber J, Dittmar KE, Wustefeld T, et al. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J. 2003;22:4003-13.
49. Poon SS, Lansdorp PM. Quantitative fluorescence in situ hybridization (Q-FISH). Curr Protoc Cell Biol. 2001;Chapter 18:Unit 18 4.
50. Vainchtein ID, Vinet J, Brouwer N, Brendecke S, Biagini G, Biber K, et al. In acute experimental autoimmune encephalomyelitis, infiltrating macrophages are immune activated, whereas microglia remain immune suppressed. Glia. 2014;62:1724-35.
51. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15-21.
52. Roussos P, Katsel P, Davis KL, Siever LJ, Haroutunian V. A system-level transcriptomic analysis of schizophrenia using postmortem brain tissue samples. Arch Gen Psychiatry. 2012;69:1205-13.
53. Anders S, Pyl PT, Huber W. HTSeq-a Python framework to work with highthroughput sequencing data. Bioinformatics. 2014;31:166-9.
54. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139-40.
55. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44-57.
56. Spinelli KJ, Taylor JK, Osterberg VR, Churchill MJ, Pollock E, Moore C, et al. Presynaptic alphα-synuclein aggregation in a mouse model of Parkinson's disease. J Neurosci. 2014;34:2037-50.
57. Sato H, Kato T, Arawaka S. The role of Ser129 phosphorylation of alphasynuclein in neurodegeneration of Parkinson's disease: a review of in vivo models. Rev Neurosci. 2013;24:115-23.
58. Fleming SM, Ekhator OR, Ghisays V. Assessment of sensorimotor function in mouse models of Parkinson's disease. J Vis Exp. 2013. doi:10.3791/50303.
59. Plaas M, Karis A, Innos J, Rebane E, Baekelandt V, Vaarmann A, et al. Alphasynuclein A30P point-mutation generates age-dependent nigrostriatal deficiency in mice. J Physiol Pharmacol. 2008;59:205-16.
60. Hebert G, Arsaut J, Dantzer R, Demotes-Mainard J. Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin. Neurosci Lett. 2003;349:191-5.
61. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol. 1999;156:50-61.
62. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis. 2006;21:404-12.
63. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38:1285-91.
64. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain. 2005; 128:2665-74.
65. Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, et al. Triggering of inflammasome by aggregated alphα-synuclein, an inflammatory response in synucleinopathies. PLoS One. 2013;8:e55375.
66. Daniele SG, Beraud D, Davenport C, Cheng K, Yin H, Maguire-Zeiss KA. Activation of MyD88-dependent TLR1/2 signaling by misfolded alphasynuclein, a protein linked to neurodegenerative disorders. Sci Signal. 2013;8:ra45.
67. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alphasynuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005;19:533-42.
68. Park JY, Paik SR, Jou I, Park SM. Microglial phagocytosis is enhanced by monomeric alphα-synuclein, not aggregated alphα-synuclein: implications for Parkinson's disease. Glia. 2008;56:1215-23.
69. Block ML, Hong JS. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans. 2007;35:1127-32.
70. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol. 2005;57:168-75.
71. Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, Lee SJ. Assembly-dependent endocytosis and clearance of extracellular alphα-synuclein. Int J Biochem Cell Biol. 2008;40:1835-49.
72. Stefanova N, Fellner L, Reindl M, Masliah E, Poewe W, Wenning GK. Toll-like receptor 4 promotes alphα-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol. 2011;179:954-63.
73. Raj DD, Moser J, van der Pol SM, van Os RP, Holtman IR, Brouwer N, et al. Enhanced microglial pro-inflammatory response to lipopolysaccharide correlates with brain infiltration and blood-brain barrier dysregulation in a mouse model of telomere shortening. Aging Cell. 2015;14:1003-13.
74. Kobayashi K, Saito K, Takagi S, Chiba K. Ligand-dependent assembly of pregnane X receptor, constitutive androstane receptor and liver X receptor is applicable to identify ligands. Drug Metab Lett. 2010;4:88-94.
75. Nagy L, Szanto A, Szatmari I, Szeles L. Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response. Physiol Rev. 2012;92:739-89.
76. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14:388-405.
77. Savage JC, Jay T, Goduni E, Quigley C, Mariani MM, Malm T, et al. Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease. J Neurosci. 2015;35:6532-43.
78. Skerrett R, Malm T, Landreth G. Nuclear receptors in neurodegenerative diseases. Neurobiol Dis. 2014;72(Pt A):104-16.
79. Norden DM, Godbout JP. Review: microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol. 2013;39:19-34.
80. Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol. 2014;10:217-24.
81. Streit WJ, Sammons NW, Kuhns AJ, Sparks DL. Dystrophic microglia in the aging human brain. Glia. 2004;45:208-12.
82. Ma L, Morton AJ, Nicholson LF. Microglia density decreases with age in a mouse model of Huntington's disease. Glia. 2003;43:274-80.
83. Hasegawa-Ishii S, Takei S, Chiba Y, Furukawa A, Umegaki H, Iguchi A, et al. Morphological impairments in microglia precede age-related neuronal degeneration in senescence-accelerated mice. Neuropathology. 2011;31:20-8.
84. Streit WJ, Xue QS. Microglial senescence. CNS Neurol Disord Drug Targets. 2013;12:763-7.
85. Frasier M, Walzer M, McCarthy L, Magnuson D, Lee JM, Haas C, et al. Tau phosphorylation increases in symptomatic mice overexpressing A30P alphasynuclein. Exp Neurol. 2005;192:274-87.
86. Maeda K. [Diagnosis and treatment of dementia in future-through the development of new drugs against Alzheimer disease]. Seishin Shinkeigaku Zasshi. 2012;114:250.
87. Kume K, Kikukawa M, Hanyu H, Takata Y, Umahara T, Sakurai H, et al. Telomere length shortening in patients with dementia with Lewy bodies. Eur J Neurol. 2012;19:905-10.
88. Eerola J, Kananen L, Manninen K, Hellstrom O, Tienari PJ, Hovatta I. No evidence for shorter leukocyte telomere length in Parkinson's disease patients. J Gerontol A Biol Sci Med Sci. 2010;65:1181-4.
89. Schurks M, Buring J, Dushkes R, Gaziano JM, Zee RY, Kurth T. Telomere length and Parkinson's disease in men: a nested case-control study. Eur J Neurol. 2014;21:93-9.